Navigation Links
Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress
Date:7/10/2009

SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced several scientific presentations at the International Society on Thrombosis and Haemostasis (ISTH) XII Congress in Boston that will feature its investigational antiplatelet drug elinogrel, a P2Y(12) ADP receptor antagonist currently in Phase II clinical development, and its oral Factor Xa inhibitor anticoagulant antidote in pre-clinical development, as well as a presentation by Portola co-founder David Phillips on new directions in antithrombotic drug discovery.

In the past six months, Portola has announced global development and commercialization agreements with Novartis for elinogrel and with Merck & Co., Inc. for betrixaban, an investigational oral Factor Xa inhibitor anticoagulant currently in Phase II clinical development.

Scientific Presentations

A Functional Pool of P2Y12 Receptors Exposed Upon Platelet Activation Persists in Mice Treated with High Dose Clopidogrel, and Can Be Blocked by Elinogrel, a Direct Acting Reversible P2Y12 Inhibitor (Presentation #PP-MO-045)

    Presenter:   Helena Haberstock-Debic
    Date: Monday, July 13, 12:30-2:15 p.m.       
    Location:  Poster Area, Platelet Biology

New Directions in Antithrombotic Drug Discovery: Pharmacological Uncoupling of Arterial thrombosis from Hemostasis (Presentation #AS-TU-026)

    Presenter: David Phillips
    Date: Tuesday, July 14, 1:15-1:45 p.m.
    Location:  Room 104 ABC, Platelets and Systemic Disorders

The Antiplatelet Effect of a New, Direct Acting, Reversible P2Y12 Inhibitor, Elinogrel (PRT060128) in Patients with High Platelet Reactivity During Clopidogrel Therapy (Presentation #PP-WE-801)

    Presenter: Paul Gurbel
    Date: Wednesday, July 15, 12:30-2:15 p.m.   
    Location:  Poster Area, Patient Oriented Studies of Antiplatelet Therapy 
     

ADP-Mediated Aggregation as a Pharmacodynamic Assay Underestimates the Antithrombotic Activity of Elinogrel, a Competitive, Reversible P2Y12 Inhibitor, Relative to Clopidogrel (Presentation #PP-TH-027)

    Presenter:  Pamela Conley
    Date: Thursday, July 16, 12:30-2:15 p.m.  
    Location:  Poster Area, Platelet Biology

Clopidogrel and Prasugrel Prolong Primary Hemostasis in the Mouse Beyond Levels Associated with P2Y12 Inhibition (Presentation #AS-TH-022)

    Presenter:  Patrick Andre
    Date: Thursday, July 16, 2:15-3:45 p.m.       
    Location:  157 ABC Oral, Platelets as Drug Targets

Reconstructed Recombinant Factor Xa as an Antidote to Reverse Anticoagulation by Factor Xa Inhibitors (Presentation #OC-TH-107)

    Presenter:  Genmin Lu
    Date: Thursday, July 16, 4:00-5:00 p.m.
    Location:  102 AB Oral, Inhibitors of Coagulation and Fibrinolysis

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concepts that are designed to provide significant advances over current treatments for cardiovascular disease, inflammatory disease and cancer. The company has global development and commercialization agreements with two of the world's leading pharmaceutical companies collectively valued at about $1B in upfront and milestone payments plus escalating double-digit royalties on future sales. Betrixaban, its oral Factor Xa inhibitor is licensed to Merck & Co., Inc., and elinogrel, its P2Y(12) ADP receptor antagonist and potential competitor for Plavix* (clopidogrel), is licensed to Novartis. Both betrixaban and elinogrel are Phase II product candidates that have best-in-class features to address the global multi-billion hospital, specialty, and chronic care anticoagulant and antiplatelet markets, respectively.

Portola also has proprietary pipeline programs focused on the discovery and development of novel, specific Syk and JAK inhibitors to treat cancer and inflammatory diseases; a thromboxane receptor antagonist, which is an aspirin replacement product for patients intolerant to aspirin; and a novel anticoagulant antidote program with the potential to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with anticoagulants worldwide in the next decade. For additional information, visit www.portola.com.

* Plavix(R) is a registered trademark of Sanofi/Aventis and Bristol Myers Squibb.


'/>"/>
SOURCE Portola Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Portola Pharmaceuticals to Host Conference Call at 11:00 a.m. Eastern Time Tomorrow to Discuss Betrixaban Partnership and Provide Corporate Update
2. Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
3. Watson Pharmaceuticals Resumes Shipment of INFeD(R) (Iron Dextran Injection, USP)
4. MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration
5. Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums
6. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
7. Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment
8. Arena Pharmaceuticals Announces Public Offering of Common Stock
9. Solvay Pharmaceuticals, Inc. Announces Commercial Availability of CREON(R) (Pancrelipase) Delayed-Release Capsules
10. Jazz Pharmaceuticals Pays Accrued Interest Under Senior Secured Notes
11. Jazz Pharmaceuticals Completes $7 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology: